Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash & Equivalents (2023 - 2026)

Prelude Therapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $84.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 91.37% to $84.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $84.8 million, a 91.37% increase, with the full-year FY2025 number at $35.3 million, up 113.44% from a year prior.
  • Cash & Equivalents hit $84.8 million in Q1 2026 for Prelude Therapeutics, up from $35.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PRLD hit a ceiling of $84.8 million in Q1 2026 and a floor of $15.2 million in Q3 2024.
  • Historically, Cash & Equivalents has averaged $41.4 million across 4 years, with a median of $33.6 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: tumbled 43.69% in 2024 and later soared 234.48% in 2025.
  • Tracing PRLD's Cash & Equivalents over 4 years: stood at $29.3 million in 2023, then tumbled by 43.69% to $16.5 million in 2024, then soared by 113.44% to $35.3 million in 2025, then soared by 140.53% to $84.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for PRLD at $84.8 million in Q1 2026, $35.3 million in Q4 2025, and $50.8 million in Q3 2025.